Exchange: NYSE·Updated 07:39 PM EST
BHVN logo

BHVN Biohaven Pharmaceutical Holding Company Ltd

$12.51
$1.26
(9.23%)
Today
Closed $12.39
$0.12
(0.97%)
After Hours
Reported EarningsOct 29
Mkt Cap$1.87B
Vol2.39M

About BHVN

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.
44

Bearish Sentiment

How do you feel about BHVN?

BiotechSwings
Approvals already landed this morning and the week is just starting Sanofi venglustat got approved today, ahead of its Nov 25 date, the first US therapy aimed at the neurological side of type 3 Gaucher. Regeneron cemdisiran was approved today too today also has data, $BHVN Phase 1 on BHV 1530 and Immutep efti the next 7 days stack up fast Nov 22 $CAPR deramiocel PDUFA, a Sunday date so Friday is the practical window Nov 22 $SVRA Molbreevi PDUFA, same Sunday setup Nov 27 BridgeBio BBP 418 PDUFA right behind them
1
4
Timefortendies77
$BHVN New Barid Upgrade from 42 to 48. Calls the SCA Drug update a surprise. I think it surprised everyone--but what a great surprise it was to know that we are closer to a commercialized drug with the H2 catalysts about to get started. For those new here, this is the calmer time before the real fireworks fly--we are about to get results of 2 placebo based trials.
6
Timefortendies77
$BHVN For those of you who want to know how the 150B Obesity Mraket plays out--just look at Lilly Earnings--GLP-1/GIP products (Mounjaro and Zepbound) account for about two-thirds (roughly 62% to 66%) of Eli Lilly’s total revenue. --Coming soon will be our T-Alpha Obesity Phase 2 update, and you know what we are going against--Lilly's BIM (the data from their solo/without GLP1 trial). Biohaven Management was clear in an interview, they want similar net weight loss as Lilly BIM (this exact % of net weight loss isn't specified as that would be proprietary) BUT WITHOUT the bad side effects. Consider what would happen if this data is good to great. This is just one of the catalysts for H2 over the next 1.5 months. Then we have XENON- closest competitor to Epilepsy on a trial pause for bad side effects using the same drug for Depr. Consider what could happen if we get our Metabolite issue fixed, then Epilepsy reads out with a much cleaner side effect profile/similar efficiency to XENON.
1
2
Timefortendies77
$BHVN This is what a successful ad-com for a Rare Disease Drug can do. • The Battle: Replimune was attempting a Class 1 resubmission for an advanced skin cancer drug (RP1). Like Biohaven, the market was highly skeptical of their trial design. • The AdCom Moment: On July 30, 2026, the FDA Cellular, Tissue, and Gene Therapies Advisory Committee met live. After a fierce debate, the independent medical panel voted 10 to 3 in favor of Replimune, stating the efficacy data was clinically meaningful. • The Reaction: The stock exploded.
1
2
taa100
$BHVN you will notice a lot of the times that before a very big increasing the price they need to manipulate the price and to lower it down scare everybody away purchase as much as they can cheap price and then the price go up I've seen this again and again only yesterday I saw it with two stocks xlab and another one and you will notice before and after hours there is a big big selling pressure and then buying pressure this is the same thing if you see a cheap price it's an opportunity to buy
5
Invescent
FDA WATCH | October 22 $BHVN — FDA accepts Vyglxia resubmission for review, with an advisory committee meeting expected. $ABUS — FDA lifts AB-101 clinical hold, allowing further U.S. development for hepatitis B. Both treatments remain investigational.
5
OnlyEverLong
$BHVN gotta hand it to the shorts for their persistence. After last week's announcement, I thought we'd have no problem staying up and over $15 ... minimum. Both providers and paitents/families are desperate for some sort of treatment for SCA and I can't see anyway the adcom doesn't vote for approval given the very clean safety profile. Of course that still doesn't guarrantee approval but all the recent developments at the FDA sure point to a strong likelihood. Troriluzole ALONE would justify the current $14/share, ~$2B market cap. Guess it just means more upside later. I don't mind waiting.
4
JFais
Case in point: Will $BHVN head higher when the market catches this nugget on Kv7? "SR waiting period has cleared and the parties are coordinating on the closing. Both parties agreed to close the transaction on December 3rd in accordance with the conditions of the agreement".
3
OnlyEverLong
$BHVN starting to look a little like a cup and handle on the daily. Would set up for a nice move up if we get good results from RISE3 and/or news about the hold being lifted and SK deal going through.
3
taa100
$BHVN a lot of short sellers jump on what they think is an opportunity date start buying short shares it's good news because squeeze time is coming
3
fazul
$BHVN If T-alpha dropped weight while adding/keeping muscle why in the world wouldn't you release results? Obviously it didn't do what they expected and are now scrambling....thats the only logical reason.....did well with Nurtec but since then lots of misses on goal
2
OnlyEverLong
$BHVN Absolutely the right call to pair taldefgrobep alfa with a GLP-1 before coming out with results
2
Valueforall
$BHVN it’s been a busy day and my attention has been focused elsewhere. Buy the dips here and now. Ready, set….go!
2
VolumeSpreadAnalysis
$BHVN Price: $14.69 Volume: Above average Catalyst: Pipeline updates on crinecerfont and rimegepant royalty news likely fueling the renewed interest. Resistance: $16.20 Support: $13.40 Bull case: A clean break above $16.20 on strong volume could open the door to a retest of recent highs. Bear case: Rejection here sends shares back toward support, with a breakdown below $13.40 signaling further downside. What I'm watching: Looking for volume confirmation on any move through resistance before adding exposure. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio:
2
Rayvio_News_Filter
$BHVN · $XTLB 🤝 Biohaven Ltd. entered an exclusive global license agreement with SK Biopharmaceuticals Co., Ltd. for its Kv7 ion channel platform, including opakalim, providing $400 million in near-term cash consideration to Biohaven. Curated for market relevance
1
Mark609
$BHVN There's no "surprise" here. Time to move on, and down. It's just the way these "we hope" things swing.
1
BapoRothstein
$BHVN So many shots on goal. We only need to hit one. We couldn’t them all. That’s what I’m talking about.
Rayvio_News_Filter
$BHVN 🏥 Biohaven Ltd. reported Phase 1 data showing BHV-1530 produced confirmed responses in 6 of 10 evaluable patients with FGFR3-altered urothelial and head and neck cancers at doses ≥3.3 mg/kg, including 3 of 5 with UC and 3 of 3 with HPV-positive HNSCC. Selected from hundreds of headlines
Merlintrader
$BHVN presented preclinical data for investigational BHV-1420 at ASN Kidney Week 2026. Not investment advice. More details in our hub.

Advertisement|Remove ads.